1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

New CEO at Thornhill Research

Discussion in 'Thornhill Research' started by anonymous, Nov 20, 2015 at 3:24 PM.

  1. anonymous

    anonymous Guest

    We are pleased to announce that the Thornhill Research Inc. Board of Directors has appointed Kipton Lade to the position of CEO effective 21 Oct 2015.

    Kipton Lade has over 25 years of experience developing, executing strategic plans and launching new medical technologies and therapies on a global level. Most recently, Mr. Lade served as General Manager for Alvimedica in Toronto, Canada. At Alvimedica, he drove all aspects of this North American business start-up including: Finance, Strategic Planning, Marketing, Sales, Business Development, and Regulatory Submissions.

    Prior to joining Alvimedica, Mr. Lade served as the Director of Sales and marketing at Boston Scientific from 2008 to 2014. His teams won major tenders with large hospital systems resulting in market leadership positions in many major medical centers and geographies across Canada. From 2006 to 2008, Mr. Lade served as Managing Director for BIOTRONIK where he established direct selling organization transitioning from a local distributor, drove revenue growth, and built strong teams in Marketing, Quality, Human Resources, Sales, Finance and Clinical Studies. From 1998 to 2006, Mr. Lade served in positions of increasing responsibility at St. Jude Medical in Toronto Canada and Sylmar, CA. As General Manager of St. Jude Medical Canada he drove revenue growth, and collaborated with key opinion leaders to launch two major clinical studies. As Senior Director Global Product Marketing at St. Jude Medical, his teams moved St. Jude from third to second in global revenue share, with the launch of high energy ICDs, innovative lead systems and new pacemaker platforms. As St. Jude Medical's Director of Emerging Indications he led a team that designed and implemented clinical studies that resulted in new indications for Atrial Fibrillation patients receiving pacemakers.

    Mr. Lade received his MBA from the University of St. Thomas, St. Paul, MN, earned an MS in Electrical Engineering from Marquette University, Milwaukee, WI, and a BS in Biomedical Engineering from Marquette University, Milwaukee, WI. Mr. Lade holds a US patent for an Implantable Syncope Monitor. He served as the President of a local school board, volunteered for the FIFA world cup and is a Dual Citizen of the USA and Canada.